Prognostic Impact of Periprocedural Bleeding and Myocardial Infarction After Percutaneous Coronary Intervention in Unselected Patients. Results From the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry

JACC: Cardiovascular Interventions

Volumn 2, Issue 11, 2009, Pages 1074-1082

  Lindsey, Jason B ^a   Marso, Steven P ^a   Pencina, Michael ^b   Stolker, Joshua M ^a   Kennedy, Kevin F ^a   Rihal, Charanjit ^c   Barsness, Greg ^c   Piana, Robert N ^d   Goldberg, Steven L ^e   Cutlip, Donald E ^f   Kleiman, Neal S ^g   Cohen, David J ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b BOSTON UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

bleeding; mortality; myocardial infarction; percutaneous coronary intervention

Indexed keywords

CLOPIDOGREL; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; THROMBIN INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 70449492704     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.09.002     Document Type: Article

References (34)

1. 3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 278 (1997) 479-484
2. Ghazzal Z., Ashfaq S., Morris D.C., et al. Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era. Am Heart J 145 (2003) 1006-1012
3. Ioannidis J.P., Karvouni E., and Katritsis D.G. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 42 (2003) 1406-1411
4. Akkerhuis K.M., Alexander J.H., Tardiff B.E., et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?. Circulation 105 (2002) 554-556
5. Ndrepepa G., Berger P.B., Mehilli J., et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51 (2008) 690-697
6. Manoukian S.V., Feit F., Mehran R., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol 49 (2007) 1362-1368
7. Feit F., Voeltz M.D., Attubato M.J., et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol 100 (2007) 1364-1369
8. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., and Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-782
9. Segev A., Strauss B.H., Tan M., Constance C., Langer A., and Goodman S.G. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome registries. Am Heart J 150 (2005) 690-694
10. Rao S.V., O'Grady K., Pieper K.S., et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96 (2005) 1200-1206
11. Kinnaird T.D., Stabile E., Mintz G.S., et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92 (2003) 930-935
12. Kong T.Q., Davidson C.J., Meyers S.N., Tauke J.T., Parker M.A., and Bonow R.O. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 277 (1997) 461-466
13. Abdelmeguid A.E., Topol E.J., Whitlow P.L., Sapp S.K., and Ellis S.G. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 94 (1996) 1528-1536
14. Iezzoni L.I. Assessing quality using administrative data. Ann Intern Med 127 (1997) 666-674
15. Wang T.Y., Peterson E.D., Dai D., et al. Patterns of cardiac marker surveillance after elective percutaneous coronary intervention and implications for the use of periprocedural myocardial infarction as a quality metric: a report from the National Cardiovascular Data Registry (NCDR). J Am Coll Cardiol 51 (2008) 2068-2074
16. Jacob S., Cohen D.J., Massaro J., Niemyski P., Maresh K., and Kleiman N. Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. Am Heart J 150 (2005) 887-892
17. Bovill E.G., Tracy R.P., Knatterud G.L., et al. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Am J Cardiol 79 (1997) 391-396
18. Peduzzi P., Concato J., Feinstein A.R., and Holford T.R. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48 (1995) 1503-1510
19. Venkitachalam L.K.K., Selzer F., Willensky R.L., et al. Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-Sponsored, Multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries. Circ Cardiovasc Intervent 2 (2009) 6-13
20. Rao S.V., Eikelboom J.A., Granger C.B., Harrington R.A., Califf R.M., and Bassand J.P. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 28 (2007) 1193-1204
21. Hill A.B. The environment and disease: association or causation?. Proc R Soc Med 58 (1965) 295-300
22. Bhatt D.L., and Topol E.J. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005?. Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 112 (2005) 906-915 discussion 923
23. Doyle B. There will be blood. J Am Coll Cardiol Intv 2 (2009) 54-55
24. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
25. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
26. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349 (1997) 1429-1435
27. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339 (1998) 436-443
28. Kastrati A., Neumann F.J., Mehilli J., et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 359 (2008) 688-696
29. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
30. Rao S., Ou F., Wang T., et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. J Am Coll Cardiol Intv 1 (2008) 379-386
31. Doyle B.J., Ting H.H., Bell M.R., et al. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. J Am Coll Cardiol Intv 1 (2008) 202-209
32. Fitts J., Ver Lee P., Hofmaster P., and Malenka D. Fluoroscopy-guided femoral artery puncture reduces the risk of PCI-related vascular complications. J Interv Cardiol 21 (2008) 273-278
33. Dauerman H.L., Applegate R.J., and Cohen D.J. Vascular closure devices: the second decade. J Am Coll Cardiol 50 (2007) 1617-1626
34. Stone G.W., Witzenbichler B., Guagliumi G., et al., HORIZONS-AMI Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358 (2008) 2218-2230